![]() ![]() Skin biopsy is recommended to distinguish progression of disease versus drug eruption (Chen L, et al JAMA Dermatology 2019 155:968-971 Hirotsu K, et al JAMA Dermatol 2021 157:700-707). Mogamulizumab and Drug Eruption bullet was added: “Mogamulizumab has been associated with a drug eruption that can clinically mimic cutaneous T-cell lymphoma.High Risk Disease: Stage III/IV and/or LDH ≥2X ULN:.Intermediate Risk Disease: Stage I/II and LDH ULN.Low Risk Disease: Allopurinol or febuxostat if intolerant to allopurinol beginning 2–3 days prior to chemo immunotherapy and continued for 10–14 days.In these patients, rasburicase should be substituted with allopurinol. Rasburicase is contraindicated in patients with a history consistent with G6PD. ➤ Glucose-6-phosphate dehydrogenase (G6PD) testing is required prior to use of rasburicase. Treatment of TLS, First-line and at retreatment for hyperuricemia was revised:.Second-line therapy and subsequent therapy for AITL, INCLUDING NODAL PTCL, TFH and FTCL:.➤ Duvelisib was added as a category 2A, other recommended regimen for both intention to proceed to transplant and no intention to transplant. ➤ Subtype, Nodal PTCL, TFH and FTCL was moved to AITL page of recommendations. Second-line therapy and subsequent therapy for PTCL-NOS EATL MEIT and ALCL:.➤ Alectinib was added as a category 2A, other recommended regimen for ALK+ ALCL only. ➤ Duvelisib was added as a category 2A, other recommended regimen for all subtypes. Initial palliative intent therapy, suggested treatment regimens for PTCL-NOS EATL MEITL and AITL, including Nodal PTCL, TFH and FTCL and AITL were moved to same page.Follow-up recommendations were added after completion of treatment for relapsed/refractory disease.Both ALCL, ALK-positive and Other histologies, Interim Restaging and Additional Therapy: Follow-up recommendations were added.Footnote “l” was revised: “…and treatment according to the ALCL, ALK-positive algorithm may be considered for ALK-negative ALCL with DUSP22 rearrangement.End-of treatment staging and follow-up recommendations were added. Listed below are abbreviations you will see if a course does not have a direct CU equivalency: NCT 0001 Not College Transferable. ![]() After first-line therapy, algorithm was revised by moving footnote, "Consider consolidative HDT/ASCR for high-risk IPI patients in CR1" into the algorithm flow. Choose your college: Choose your courses: Clemson Equivalent Course.➤ Essential, 3rd bullet, 1st sub-bullet: EBER-ISH was removed and added as a separate bullet. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |